Elisa Landoni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elisa Landoni has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anna Jin
University of North Carolina at Chapel Hill 4 Lineberger Comprehensive Cancer Center, School of Medicine Chapel Hill, North Carolina
1 shared publication - Austin J. Hepperla
University of North Carolina at Chapel Hill 4 Lineberger Comprehensive Cancer Center, School of Medicine Chapel Hill, North Carolina
1 shared publication - Barbara Savoldo
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
1 shared publication - Caitlyn McComb
University of North Carolina at Chapel Hill 4 Lineberger Comprehensive Cancer Center, School of Medicine Chapel Hill, North Carolina
1 shared publication - Ian J. Davis
University of North Carolina at Chapel Hill 1 Department of Pediatrics, School of Medicine Chapel Hill, North Carolina
1 shared publication - Justin R. Sperlazza
University of North Carolina at Chapel Hill 1 Department of Pediatrics, School of Medicine Chapel Hill, North Carolina
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF16
GD2 Induction by Combination Chromatin-Directed Inhibitors Enhances Targeting of Ewing Sarcoma and Osteosarcoma by CAR T Cells
Adoptive cellular therapies depend on the adequate expression of target antigens on tumors. The disialoganglioside GD2, a target of chimeric antigen receptor (CAR) T cells (GD2.CAR T cells) and monoclonal antibodies, is variably expressed in Ewing sarcoma and osteosarcoma. We investigated the ability of chromatin-directed small molecules to enhance tumor GD2 and sensitize tumors to GD2.CAR T cells. Although the EZH2 inhibitor tazemetostat increased GD2 levels in culture and in xenografted mice, tazemetostat treatment was unable to maintain sufficient tumor GD2 levels necessary to enable tumor control in a metastatic xenograft model. We performed a screen of chromatin-directed small molecules to identify additional compounds capable of regulating tumor GD2 and identified multiple compounds, including the HDAC inhibitor entinostat and the DOT1L inhibitor pinometostat. Both compounds greatly enhanced tumor GD2 expression by tazemetostat in culture but did not limit CAR T-cell activity. In multiple xenograft models, the combination of tazemetostat and entinostat resulted in enhanced tumor GD2 expression and led to long-term tumor control by GD2.CAR T cells. These data offer preclinical support for the incorporation of chromatin-directed inhibitors into ongoing CAR T-cell trials for Ewing sarcoma and osteosarcoma.
- 30 October 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF16
Open AccessGD2 Induction by Combination Chromatin-Directed Inhibitors Enhances Targeting of Ewing Sarcoma and Osteosarcoma by CAR T Cells
Adoptive cellular therapies depend on the adequate expression of target antigens on tumors. The disialoganglioside GD2, a target of chimeric antigen receptor (CAR) T cells (GD2.CAR T cells) and monoclonal antibodies, is variably expressed in Ewing sarcoma and osteosarcoma. We investigated the ability of chromatin-directed small molecules to enhance tumor GD2 and sensitize tumors to GD2.CAR T cells. Although the EZH2 inhibitor tazemetostat increased GD2 levels in culture and in xenografted mice, tazemetostat treatment was unable to maintain sufficient tumor GD2 levels necessary to enable tumor control in a metastatic xenograft model. We performed a screen of chromatin-directed small molecules to identify additional compounds capable of regulating tumor GD2 and identified multiple compounds, including the HDAC inhibitor entinostat and the DOT1L inhibitor pinometostat. Both compounds greatly enhanced tumor GD2 expression by tazemetostat in culture but did not limit CAR T-cell activity. In multiple xenograft models, the combination of tazemetostat and entinostat resulted in enhanced tumor GD2 expression and led to long-term tumor control by GD2.CAR T cells. These data offer preclinical support for the incorporation of chromatin-directed inhibitors into ongoing CAR T-cell trials for Ewing sarcoma and osteosarcoma.